JAPAN-SANITARY-EQUIP-IND
26.7.2022 04:02:07 CEST | Business Wire | Press release
The Japan Sanitary Equipment Industry Association, which is composed of Japanese companies engaged in the manufacturing of toilets (Headquarters: Nagoya, Aichi, Japan. President: Noriaki Kiyota [President & Representative Director of TOTO Ltd.], hereinafter “Association”) is proud to announce that the number of warm water spray seat shipments since the industry began tracking statistics (1987) has reached 100 million units as of June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005331/en/
The Road to 100 Million Units
The start of importation and sale of toilets and toilet seats with warm-water washing functionality into Japan in 1964 sparked major changes of “washing bottoms” in Japanese toilets. At first, sales were targeted towards medical facilities, and use was not widespread. Later, domestic production began, and companies launched initiatives including product development and improvement, and sales promotions to encourage use in common households. Eventually, more Japan residents grew to recognize these products after a TV commercial in 1982. Once people experienced the comfort of a warm toilet seat and the refreshing satisfaction of rear cleansing, they were unable to live without it. Good reputations spread, and these products finally became accepted by the general public.
Association member companies have been working continuously to evolve these products and to promote further use, by making new proposals and implementing updates that reflect consumer needs across multiple aspects, including function, comfort, hygiene, design, and energy efficiency. Currently in 2022, usage rates in general households have surpassed 80%, which means that it can finally be said that these products are estimated to be used in the majority of general households with flushable toilets. Likewise, because warm water spray seats have a good reputation for comfort, they have also been widely adopted for use in public places such as office buildings, commercial facilities, hotels, trains, and train stations.
Must-Have Item for Japanese Bathrooms
According to an awareness survey conducted by the Association in 2022 among warm water spray seat users in Japan, the main reason for use was “It’s sanitary and feels good to use.” In addition, 97% of the respondents would like to continue to use the warm-water washing toilet seats, indicating that once they use them, they find it so comfortable that they will not want to give them up.
Meanwhile, outside of Japan, demands are growing in other countries across the Americas, Europe, Asia, and the Middle East in recent years as interest in hygiene continues to rise, and the international market for warm water spray seats continues to expand every year. In particular, a sudden rise in demand was seen in North America in 2020, stoking anticipation for wider usage in the near future.
The Association and its members, Japanese manufacturers of warm water spray seats, are dedicated to making real improvements in restroom culture worldwide through the wider usage of sanitary and comfortable warm water spray seats in every country.
Awareness Survey for Warm Water Spray Seat Users
Survey Method: Online questionnaire
Survey Targets: Users of warm-water washing toilet seats, aged 10 to 79, living in Japan, 150 respondents for each age group, total of 2,100 respondents
Survey Period: February 4, 2022 (Friday) to February 7, 2022 (Sunday)
[ Survey Results Summary ]
The main reason for use was “It’s sanitary and feels good to use.”
When asked why they use warm water spray seats, most respondents said “It removes waste well and keeps me clean” (82%) and nearly half of respondents said “It feels good and refreshing” (48%).
97% of respondents said “I want to continue using it.”
Regarding their intention to continue the use of warm-water toilet seats in the future, 86% of respondents said they would like to continue to use them, and 11% said they would rather continue to use them.
Learn More About the Japan Sanitary Equipment Industry Association
The Japan Sanitary Equipment Industry Association is an industry organization made up of toilet equipment manufacturers that handle products such as sanitary fixtures (large and small toilets) and warm-water washing toilet seats.
The Japan Sanitary Equipment Industry Association operates the JAPAN TOILET INFORMATION website, which is dedicated to providing information on toilet conditions in Japan (usage, signage, etc.) for foreign visitors to Japan.
(https://www.sanitary-net.com/utsukushitoilet/en/
)
[ Member Companies (As of June 2022, in alphabetical order) ]
Aisin Corporation, Asahi Eito Co., Ltd., Janis Ltd., Lixil Corporation, Panasonic Holdings Corporation, SAN-EI Faucet Mfg Co., Ltd, Toshiba Lifestyle Products & Services Corporation, TOTO Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
